Panelists discuss how differences in trial designs, including inclusion criteria, dosing, and end points, influence clinical decision-making in the use of CDK4/6 inhibitors for HR+/HER2– early breast cancer (eBC), with a focus on the NATALEE trial’s analysis of patients with no or low nodal involvement, and how recent expanded approval of ribociclib for high-risk node-positive and node-negative eBC patients guides the identification of ideal candidates based on clinical factors.
Please describe notable differences in the trial designs or analyses (eg, inclusion criteria, dosing, end points) with these CDK4/6 inhibitors in eBC.
How do these differences impact your clinical decision-making?
The latest NATALEE trial analysis (N0 subgroup) examines patients with no or low nodal involvement; can you please describe your experience with this patient population?
With the recent expanded approval of ribociclib for node-positive and node-negative HR+/HER2– eBC patients with a high risk of recurrence, what patient characteristics or clinical factors make someone an ideal candidate for adjuvant ribociclib?